Squarepoint’s Palvella Therapeutics PVLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-5,176
Closed -$791K – 5156
2026
Q2
$791K Sell
5,176
-7,891
-60% -$958K ﹤0.01% 3086
2026
Q1
$1.63M Buy
+13,067
New +$1.36M ﹤0.01% 2360
2024
Q2
– Sell
-1,823
Closed -$26.7K – 4761
2024
Q1
$26.7K Buy
+1,823
New +$25.4K ﹤0.01% 3911
2021
Q4
– Sell
-445
Closed -$184K – 3593
2021
Q3
$184K Sell
445
-1,175
-73% -$409K ﹤0.01% 2526
2021
Q2
$496K Buy
+1,620
New +$355K ﹤0.01% 2134
2020
Q4
– Sell
-218
Closed -$36K – 3320
2020
Q3
$36K Buy
+218
New +$49.6K ﹤0.01% 2395
2020
Q2
– Sell
-1,022
Closed -$186K – 2565
2020
Q1
$186K Buy
1,022
+462
+83% +$116K ﹤0.01% 1499
2019
Q4
$162K Buy
+560
New +$155K ﹤0.01% 2268
2019
Q3
– Sell
-135
Closed -$51K – 2728
2019
Q2
$51K Buy
+135
New +$40.3K ﹤0.01% 2280
2018
Q3
– Sell
-354
Closed -$143K – 2268
2018
Q2
$143K Buy
354
+126
+55% +$60K ﹤0.01% 1596
2018
Q1
$124K Sell
228
-438
-66% -$271K ﹤0.01% 1556
2017
Q4
$402K Buy
+666
New +$310K 0.01% 1327

Other funds holding PVLA

Squarepoint's PVLA Position: Q3 2026 in Review

Squarepoint sold out of Palvella Therapeutics (PVLA) in Q3 2026, closing a stake of 5,176 shares — an estimated $791K sold.

Squarepoint first reported a position in PVLA in Q4 2017 and held it in 12 quarters. The position peaked at $1.63M in Q1 2026. 196 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

  • Squarepoint reported no remaining Palvella Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Squarepoint sold 5,176 Palvella Therapeutics shares in Q3 2026, an estimated $791K.
  • Squarepoint first reported a position in Palvella Therapeutics in Q4 2017 and held it in 12 quarters.
  • Squarepoint's Palvella Therapeutics position peaked at $1.63M in Q1 2026.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.